Joern Aldag

Joern Aldag is Chief Executive Officer of HOOKIPA Pharma, a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform designed to reprogram the body’s immune system. Before joining HOOKIPA in June 2016, Joern was CEO of NASDAQ-listed uniQure N.V, a company pioneering gene therapy. Under his leadership from 2009-2015, uniQure received the first-ever approval of a gene therapy product by the European Medicines Agency, built a pipeline of gene therapy products across several disease areas, obtained approximately $200M through its NASDAQ-listing and follow-on, and closed a multi-billion dollar collaboration in cardiovascular gene therapy. From 1997-2008, Joern was President and CEO of Evotec AG, where he closed many alliances with leading life-science companies, listed the Company on the Frankfurt Stock Exchange and NASDAQ, and managed the acquisition of LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis Inc. Joern co-founded and successfully sold GPCR-company G7 Therapeutics AG to Sosei Heptares. From 2007 to 2018 Joern was Chairman of SIX-listed Molecular Partners AG, Zurich, Switzerland. Joern is a Non-Executive Director at Idorsia Pharmaceuticals Ltd. and Chairman and Non-Executive Director at GeneSpire Srl, a preclinical stage gene therapy company. He holds business degrees from the European Business School and Harvard Business School (AMP).